(c) 2024 PillSync.com

carvedilol 3.125 MG Oral Tablet

1 INDICATIONS AND USAGE Carvedilol tablets are an alpha/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients( 1.2 ) hypertension( 1.3 ) 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions ( 7.4 ), Clinical Studies ( 14.1 )] . 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies ( 14.2 )] . 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies ( 14.3 , 14.4 )] . It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions ( 7.2 )] .

Zydus Pharmaceuticals (USA) Inc.


5 years ago ROUND WHITE Z 1 carvedilol 3.125 MG Oral Tablet

ROUND WHITE Z 1

5 years ago ROUND WHITE Z 1 carvedilol 3.125 MG Oral Tablet

Z 1 ROUND WHITE

16 HOW SUPPLIED/STORAGE AND HANDLING

CARVEDILOL Tablets USP, 3.125 mg are white to off-white, round, biconvex, film-coated tablets debossed with 'Z' on one side and '1' on other side and are supplied as follows: NDC-68382-092-17 in bottles of 28 tablets with child-resistant closure NDC-68382-092-01 in bottles of 100 tablets NDC-68382-092-05 in bottles of 500 tablets

CARVEDILOL Tablets USP, 6.25 mg are white to off-white, round, biconvex, beveled edge, film-coated tablets debossed with 'ZC40' on one side and plain on other side and are supplied as follows: NDC-68382-093-17 in bottles of 28 tablets with child-resistant closure NDC-68382-093-01 in bottles of 100 tablets NDC-68382-093-05 in bottles of 500 tablets

CARVEDILOL Tablets USP, 12.5 mg are white to off-white, round, biconvex, beveled edge, film-coated tablets debossed with 'ZC41' on one side and plain on other side and are supplied as follows: NDC-68382-094-17 in bottles of 28 tablets with child-resistant closure NDC-68382-094-01 in bottles of 100 tablets NDC-68382-094-05 in bottles of 500 tablets

CARVEDILOL Tablets USP, 25 mg are white to off-white, round, biconvex, beveled edge, film-coated tablets debossed with 'ZC42' on one side and plain on other side and are supplied as follows: NDC-68382-095-17 in bottles of 28 tablets with child-resistant closure NDC-68382-095-01 in bottles of 100 tablets NDC-68382-095-05 in bottles of 500 tablets Storage Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, light-resistant container.


More pills like ROUND Z 1

Related Pills

carvedilol 6.25 MG Oral Tablet

Zydus Pharmaceuticals (USA) Inc.

carvedilol 12.5 MG Oral Tablet

Zydus Pharmaceuticals (USA) Inc.

carvedilol 25 MG Oral Tablet

Zydus Pharmaceuticals (USA) Inc.

carvedilol 3.125 MG Oral Tablet

Zydus Pharmaceuticals (USA) Inc.

Zantac 150 MG Oral Tablet

Boehringer Ingelheim Pharmaceuticals Inc.

Maximum Strength Zantac Ranitidine 150 MG Oral Tablet Zantac

Boehringer Ingelheim Pharmaceuticals Inc.

Maximum Strength Zantac Ranitidine 150 MG Oral Tablet Zantac

Boehringer Ingelheim Pharmaceuticals Inc.












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site